Navigation Links
The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry
Date:12/12/2013

MUMBAI, December 12, 2013 /PRNewswire/ --

A comparative analysis and assessment of TCR technologies, pipelines and companies from an industry perspective

Therapeutic monoclonal antibodies have become an increasingly successful treatment modality with sales of US$ 65 bln in the year 2012 and with an average (continuous) annual growth rate from 2006 to 2012 of 18.9%. While antibody technologies are steadily evolving, the spectrum of drug gable targets for monoclonal antibodies has remained limited to extracellular antigens, albeit including proteins, carbohydrates and glycolipids.

     (Logo: http://photos.prnewswire.com/prnh/20130128/590935)

Bharat Book Bureau presents the report entitled "The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry" published in October 2013 describes chances and pitfals in exploiting the opportunities which offers the engineered T-cell receptor as integral part of fusion proteins, antibodies and cellular products. The key success factors are highlighted, the technical challenges described and solutions presented. (http://www.bharatbook.com/healthcare-market-research-reports/the-engineered-t-cell-receptor-in-fusion-proteins-antibodies-cells-emerging-opportunities-for-the-biopharmaceutical-industry.html)

Access to drug gable, IP-protected and validated new targets are a major bottleneck in the biopharmaceutical industry. Technologies which can deliver both new targets and the corresponding treatment modality, can expect significant financial acknowledgement.

The T-cell receptor (TCR) has recently emerged as a means to target peptide antigens derived from intracellular proteins, however, in a major histocompatibility complex (MHC)-restricted manner. The first companies have overcome significant technical hurdles in putting together a library of viable new TCR-targeted antigens and establish the corresponding standardized protein- and cell-based therapeutic frameworks.

Benefits from the report:

  • Identify players in the field, from industry and academia;
  • Find out which TCR technologies are valued by Big Parma and Biotech;
  • Understand the value of intracellular antigens targeted by the TCR;
  • Recognize the challenges of TCR-based therapeutics and their solutions;
  • Learn which TCR-based therapeutics are attractive for partnering;
  • Find out which TCR therapeutic approaches are not yet tapped.

Table of Contents

  • Executive Summary
  • Introduction
    • The T-Cell Receptor
    • TCR Fusion Proteins
    • Altor Bioscience
    • Overview
    • Financing history
    • IP protection
    • Partnering
    • STAR technology
    • Binding affinity of scTCRs
    • Manufacturing of STAR molecules
    • Targets for scTCRs
    • Generation of scTCRs
    • Other applications of STAR molecules
    • STAR pipeline
    • ALT-801
    • Preclinical characterization of ALT-801
    • Clinical results of studies with ALT-801
    • Ongoing clinical studies with ALT-801
    • Safety of ALT-801 in clinical studies
    • Clinical immunogenicity of ALT-801
    • Clinical pharmacokinetics of ALT-801
    • ALT-802
    • Assessment
    • Immunocore
    • Corporate development of Immunocore
    • Stability and solubility of TCRs
    • Affinity of monoclonal TCRs (mTCR)
    • Effector function for mTCR
    • Target discovery for mTCRs
    • Preclinical experience with mTCRs
    • ImmTAC clinical lead program
    • Partnering
    • Assessment
    • TCR-Like (TCRL) Antibodies

      Eureka Therapeutics & Memorial Sloan-Kettering Cancer Center

      Target of TCRL antibody

      Generation of TCRL antibody

      Preclinical characterization of TCRL antibody

      Intellectual property

      Corporate background

      Assessment

      Applied Immune Technologies

      Corporate background

      Financial history

      Cancer target

      Technologies

      Viral targets

      Generation of TCRL antibodies

      Assessment

    • TCR-Transfected T-Cells

      Adaptimmune

      Corporate Background

      Overview of manufacturing

      The TCR engineering process

      TCR-transfected T-cells versus CAR-transfected T-clls

      Clinical R&D in cancer

      Clinical HIV study with TCR T-cells

      Assessment

      Academic Studies with TCR-Transfected T-Cells

    • Artificial TCR T-Cells: Chimeric Antigen Receptor (CAR) T-Cells

      CAR-modified T-cells for cancer

      Background

      Clinical experience with CAR-modified T-cells

      The three generations of CAR-Modified T-cells

      Assessment

      Autologous CAR-Modified T-Cells

      Novartis & The University of Pennsylvania

      Celgene & bluebird bio & Baylor College of Medicine

      Kite Parma

      Allogeneic CAR-Modified T-Cells

      Cellectis

      CAR-Modified Induced Pluripotent Stem Cells

    • Tumor-Infiltrating Lymphocytes (TILs)

      Lion Biotechnologies

    • Opportunity Analysis for TCR-based Products and Technologies
    • References
    • Corporate R&D Pipelines

      Adaptimmune

      Altor Bioscience

      Immunocore

      Lion Biotechnologies


    Request for sample pages: http://www.bharatbook.com/RequestSample.asp?pid=230115

    For more information on the report: http://www.bharatbook.com/healthcare-market-research-reports/the-engineered-t-cell-receptor-in-fusion-proteins-antibodies-cells-emerging-opportunities-for-the-biopharmaceutical-industry.html

    Related Reports:

    Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2013

    Global Cancer Monoclonal Antibodies Pipeline Analysis

    The 2013-2018 Outlook for Autoimmune Disease Therapeutics in India

    Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy - Pipeline Review, H2 2012

    T-Cell Lymphomas - Pipeline Review, H2 2013


    Related Category:

    T-cell

    Lymphoma

    Antibodies

    Cancer

    Immune

    Stem Cell


    About Bharat Book Bureau

    Bharat Book Bureau is the leading market research information aggregator that provides market research reports, industry analysis, company profiles, business reports, country reports, newsletters and online databases. Our clients include Corporate, Consulting firms, and Academic Institutions and Government departments across the globe. Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. The market research reports we provide, help global companies examine the different markets before setting up a business or expanding into different countries across the world. They give a complete perspective on the current market scenario, trends, segments and future outlook.


    '/>"/>

SOURCE Bharat Book Bureau
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells Industry Trend: Worldwide Industry Latest Market Share, Investment Trends, Growth, Size, Strategy
2. The reins of Casimir: Engineered nanostructures could offer way to control quantum effect
3. Bioengineered Skin Substitutes to 2016. Products, Players, Markets and Growth Prospects
4. New bioengineered ears look and act like the real thing
5. Using 3-D printing and injectable molds, bioengineered ears look and act like the real thing
6. Will new methods that increase blood flow to bone implants improve viability of engineered bone tissue?
7. Highly efficient production of advanced biofuel by metabolically engineered microorganism
8. Preclinical data shows 100 percent prevention and treatment of influenza with engineered human antibody
9. Genetically engineered bacteria prevent mosquitoes from transmitting malaria
10. Microbes may be engineered to help trap excess CO2 underground
11. SentoClone International AB Significantly Strengthens its Global Patent Portfolio Covering its Clinical Stage Sentinel Node-derived CD4 T-cell Cancer Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):